S.Biomedics

At a glance

S.Biomedics filed 28 disclosures in the last 12 months, including 3 5% holder, 2 issuance and 1 insider. The most recent key filing was on Aug 31.

Revenue for 2025 was ₩16.5B, up 20.5% on 2024. It made an operating loss of ₩8.3B. Debt was 146% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩9.2B and operating loss of ₩6.7B.

The 2025 annual report lists 52 employees with an average tenure of 5.2 years and average pay of ₩42.4M, #1708 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩71.9M each on average. It paid no cash dividend for 2025. 강세일 and related parties held 21.45% at year end.

From the 2025 annual report

Staff: 52 (24 men, 28 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩2.6B. Directors and auditors: 8, paid ₩575M in total.

No cash dividend was paid for 2025.

Largest shareholder

강세일 holds 16.88%; with 7 related parties the group holds 21.45% of common shares at year end (from 21.24% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary